SVF
Level B· Emerging Clinical EvidenceClinical Trial

Regenerative endoscopy for the treatment of difficult gastrointestinal defects: results from a pilot trial.

Nachira D., Pontecorvi V., Trivisonno A., Papi M., Matteo MV., Bove V.

Clinical Trial with a reported sample of 30 on Hip, published in Endoscopy (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Endoscopy (2026)
Country
Germany
Reported sample size
30
PMID
40719105
DOI
10.1055/a-2665-1777

Abstract (original English)

Gastrointestinal (GI) defects with inflamed, fibrotic edges are often refractory to traditional endoscopic treatments. This study evaluates the efficacy and safety of endoscopically delivered stromal vascular fraction from autologous adipose tissue (tSVFem), which promotes tissue regeneration in upper and lower GI defects without additional patient risk or cost. This pilot trial involved patients with GI defects accessible by endoscopy after traditional treatments had failed. The tSVFem was derived from harvested hip fat, which was processed and injected endoscopically into the defect margins. The primary outcome was complete defect resolution. Secondary outcomes included treatment frequency, procedure-related adverse events, and recurrence. 30 patients were included: 15 with esophageal defects (median diameter 6 mm) and 15 with rectal defects (median diameter 5 mm). Of the 15 esophageal defects, 14 showed complete resolution after tSVFem injection (10 after one injection and 4 after two injections). The overall resolution rate for rectal defects was 60% (six after one treatment, one after two treatments, and two after three or four treatments). The resolution rate was 5/9 for rectal defects communicating with the urinary tract and 4/6 for those communicating with other organs. No intraprocedural or postprocedural adverse events or defect recurrence occurred. These results sugg

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies exist, but sample sizes, methodology, or follow-up remain limited, so conclusions are not firm.

How we grade evidence
HumansPilot ProjectsMaleMiddle AgedFemaleAgedAdipose TissueEndoscopy, GastrointestinalTransplantation, AutologousAdult
Hip
View on PubMedDOI

Related research